文献速递肝病

肝移植候选者COVID-19:移植前与移植后结局——ELITA/ELTR多中心队列研究

COVID-19 in liver transplant candidates: pretransplant and post-transplant outcomes - an ELITA/ELTR multicentre cohort study.
PubMed 文献 · Gut · 2021-07-19

该研究基于欧洲11国33中心2020年2月至11月连续收集的136例成人肝移植候选者中实验室确诊SARS-CoV-2感染病例(其中113例患COVID-19),分析移植前死亡及移植后生存。结果显示37/113(32.7%)死亡,呼吸衰竭为主要死因(33/37,89.2%);60天死亡风险两波疫情无显著差异;Lab-MELD≥15和就诊时呼吸困难为独立负性因素。26例后续接受肝移植,25例(96%)存活。

要点

  • 肝移植候选者感染COVID-19后死亡率为32.7%,呼吸衰竭为主要死因。
  • 失代偿期肝硬化且Lab-MELD≥15者死亡率达45%。
  • 既往有症状SARS-CoV-2感染不影响移植后早期生存(96%)。

核心结论

  • 肝移植候选者感染COVID-19后死亡率升高(32.7%),失代偿期肝硬化且Lab-MELD≥15者达45%。

研究设计与样本

  • 欧洲11国33中心连续收集的成人肝移植候选者COVID-19登记队列研究,共136例实验室确诊SARS-CoV-2感染,其中113例患COVID-19。

主要发现

  • 37/113(32.7%)患者死亡,中位死亡时间18(10-30)天,呼吸衰竭为主要死因(33/37,89.2%)。
  • 60天死亡风险第一波为35.3%(95%CI 23.9%-50.0%),第二波为26.0%(95%CI 16.2%-40.2%),无显著差异。
  • 多因素Cox回归显示Lab-MELD≥15(MELD 15-19:HR 5.46,95%CI 1.81-16.50;MELD≥20:HR 5.24,95%CI 1.77-15.55)和就诊时呼吸困难(HR 3.89,95%CI 2.02-7.51)为死亡的独立负性因素。
  • 26例后续接受肝移植,中位等待时间78.5(IQR 44-102)天,中位随访118天(IQR 31-170)时25例(96%)存活。

临床怎么用

  • 对肝移植候选者应严格执行预防措施,并紧急评估该人群疫苗接种效力。
  • 既往有症状SARS-CoV-2感染不排除后续肝移植,移植后早期生存良好(96%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Explore the impact of COVID-19 on patients on the waiting list for liver transplantation (LT) and on their post-LT course. DESIGN: Data from consecutive adult LT candidates with COVID-19 were collected across Europe in a dedicated registry and were analysed. RESULTS: From 21 February to 20 November 2020, 136 adult cases with laboratory-confirmed SARS-CoV-2 infection from 33 centres in 11 European countries were collected, with 113 having COVID-19. Thirty-seven (37/113, 32.7%) patients died after a median of 18 (10-30) days, with respiratory failure being the major cause (33/37, 89.2%). The 60-day mortality risk did not significantly change between first (35.3%, 95% CI 23.9% to 50.0%) and second (26.0%, 95% CI 16.2% to 40.2%) waves. Multivariable Cox regression analysis showed Laboratory Model for End-stage Liver Disease (Lab-MELD) score of ≥15 (Model for End-stage Liver Disease (MELD) score 15-19, HR 5.46, 95% CI 1.81 to 16.50; MELD score≥20, HR 5.24, 95% CI 1.77 to 15.55) and dyspnoea on presentation (HR 3.89, 95% CI 2.02 to 7.51) being the two negative independent factors for mortality. Twenty-six patients underwent an LT after a median time of 78.5 (IQR 44-102) days, and 25 (96%) were alive after a median follow-up of 118 days (IQR 31-170). CONCLUSIONS: Increased mortality in LT candidates with COVID-19 (32.7%), reaching 45% in those with decompensated cirrhosis (DC) and Lab-MELD score of ≥15, was observed, with no significant difference between first and second waves of the pandemic. Respiratory failure was the major cause of death. The dismal prognosis of patients with DC supports the adoption of strict preventative measures and the urgent testing of vaccination efficacy in this population. Prior SARS-CoV-2 symptomatic infection did not affect early post-transplant survival (96%).

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Belli LS, Duvoux C, Cortesi PA, et al. COVID-19 in liver transplant candidates: pretransplant and post-transplant outcomes - an ELITA/ELTR multicentre cohort study. Gut. 2021. PMID: 34281984. doi:10.1136/gutjnl-2021-324879

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。